Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17993837 | 0.89 | ADRA1A (0.45) | BAZ2BMCHR1ADRA1AMEN1KMT2A | |
| SCHEMBL2185371 | 0.84 | CHRNA7 (0.64) | BAZ2BACHEALDH1A1GAAL3MBTL1 | |
| SCHEMBL13194931 | 0.79 | CHRNA7 (0.69) | BAZ2BACHEALDH1A1GAATHRB | |
| SCHEMBL16854929 | 0.78 | L3MBTL1 (0.44) | BAZ2BACHEALDH1A1GAATHRB | |
| SCHEMBL16624301 | 0.77 | BAZ2B (0.54) | BAZ2BACHESIGMAR1ADRA1A | |
| SCHEMBL28661381 | 0.77 | BAZ2B (0.64) | BAZ2BACHEALDH1A1GAAMEN1 | |
| SCHEMBL2186665 | 0.75 | L3MBTL1 (0.70) | BAZ2BACHEALDH1A1GAAL3MBTL1 | |
| SCHEMBL16624341 | 0.75 | KDM4E (0.64) | BAZ2BL3MBTL1CHRNA7ADRA1AMEN1 | |
| SCHEMBL29293499 | 0.75 | BAZ2B (0.44) | BAZ2BACHEALDH1A1L3MBTL1SIGMAR1 | |
| SCHEMBL21153982 | 0.74 | BAZ2B (0.43) | BAZ2BACHEALDH1A1GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-18 | — | — | US | disclosed |
| EP-3053917-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nissan Chemical Industries, Ltd. (JP) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015050212-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | 日産化学工業株式会社 | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1I, CACNA1G, CACNA1H | BAZ2B 3141/4885ACHE 2037/4885ALDH1A1 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.